Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2070]

A precision medicine approach to therapeutic resistance using KEAP1 somatic...

Dr Gerald Batist - McGill University - Segal Cancer Centre, Montreal, Canada

A precision medicine approach to therapeutic resistance using KEAP1 somatic mutations ( Dr Gerald Batist - McGill University - Segal Cancer Centre, Montreal, Canada )

Gene expression in primary non-small cell lung cancer as a predictor of brain...

Dr Jair Bar - Sheba Medical Center, Tel Hashomer, Israel

Gene expression in primary non-small cell lung cancer as a predictor of brain metastases ( Dr Jair Bar - Sheba Medical Center, Tel Hashomer, Israel )

Rewriting the code of life: CRISPR-Cas9 genome editing

Prof Jennifer Doudna - University of Berkeley, Berkeley, USA

Rewriting the code of life: CRISPR-Cas9 genome editing ( Prof Jennifer Doudna - University of Berkeley, Berkeley, USA )

Direct targeting of STAT3 alone and in combination with immune checkpoint...

Dr David Tweardy - The University of Texas MD Anderson Cancer Center, Houston...

Direct targeting of STAT3 alone and in combination with immune checkpoint inhibitors to treat solid tumours ( Dr David Tweardy - The University of Texas MD Anderson Cancer Center, Houston, USA )

Integration of DNA and RNA investigations in clinical trials: A laboratory...

Brandon Young - Bowden WIN Precision Oncology Laboratory, Murrieta, USA

Integration of DNA and RNA investigations in clinical trials: A laboratory challenge ( Brandon Young - Bowden WIN Precision Oncology Laboratory, Murrieta, USA )

Optimising patient enrolment and efficacy of precision oncology clinical trials

Prof Apostolia-Maria Tsimberidou - The University of Texas MD Anderson Cancer...

Optimising patient enrolment and efficacy of precision oncology clinical trials ( Prof Apostolia-Maria Tsimberidou - The University of Texas MD Anderson Cancer Center, Houston, USA )

Comment: POLO III trial for metastatic pancreatic cancer

Prof Heinz-Josef Lenz - USC Norris Comprehensive Cancer Center, Los Angeles, USA

Comment: POLO III trial for metastatic pancreatic cancer ( Prof Heinz-Josef Lenz - USC Norris Comprehensive Cancer Center, Los Angeles, USA )

CD-19 mutation frequency after blinatumomab treatment is lower than after CAR T...

Dr Michaela Kotrova - Universitätsklinikum Schleswig-Holstein, Kiel, Germany

CD-19 mutation frequency after blinatumomab treatment is lower than after CAR T-cell therapy ( Dr Michaela Kotrova - Universitätsklinikum Schleswig-Holstein, Kiel, Germany )

Safety and efficacy of escalating doses of Hu5F9-G4 with rituximab in patients...

Dr Mark Roschewski - National Cancer Institute, Bethesda, USA

Safety and efficacy of escalating doses of Hu5F9-G4 with rituximab in patients with R/R DLBCL and indolent lymphoma ( Dr Mark Roschewski - National Cancer Institute, Bethesda, USA )

Combination of pegcrisantaspase and venetoclax in acute myeloid leukaemia

Dr Ashkan Emadi - University of Maryland Medical Centre, Maryland, USA

Combination of pegcrisantaspase and venetoclax in acute myeloid leukaemia ( Dr Ashkan Emadi - University of Maryland Medical Centre, Maryland, USA )

CLL12 trial: Ibrutinib in previously untreated, asymptomatic early-stage CLL

Dr Othman Al-Sawaf - University of Cologne, Cologne, Germany

CLL12 trial: Ibrutinib in previously untreated, asymptomatic early-stage CLL ( Dr Othman Al-Sawaf - University of Cologne, Cologne, Germany )

Chemoimmunotherapy or BTK inhibition for patients with CLL

Dr Othman Al-Sawaf - University of Cologne, Cologne, Germany

Chemoimmunotherapy or BTK inhibition for patients with CLL ( Dr Othman Al-Sawaf - University of Cologne, Cologne, Germany )

More from ecancer